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Introduction {#cjp290-sec-0001}
============

Human prion diseases constitute a group of fatal neurological disorders classified according to their clinical, genetic, and neuropathological features as sporadic, familial, or acquired [1](#cjp290-bib-0001){ref-type="ref"}. A common feature of human prion diseases is the conformational change of a normal endogenous protein, the prion protein (PrP^C^), to the misfolded and disease‐associated form PrP^Sc^, which accumulates in central nervous system tissue [2](#cjp290-bib-0002){ref-type="ref"}. Currently, variant Creutzfeldt‐Jakob disease (vCJD) in humans is considered the only zoonotic human prion disease, with evidence suggesting that it is caused by oral exposure to the infectious agent associated with bovine spongiform encephalopathy (BSE) that affected cattle in the United Kingdom and Europe [3](#cjp290-bib-0003){ref-type="ref"}. Although PrP^Sc^ accumulation occurs primarily in the brain in human prion disease, a notable feature of vCJD is the detection of PrP^Sc^ in the lymphoid tissues including spleen, tonsil, and appendix [2](#cjp290-bib-0002){ref-type="ref"}, [4](#cjp290-bib-0004){ref-type="ref"}. Retrospective prevalence studies, based on the analysis of anonymized appendectomy samples for the presence of PrP^Sc^, estimate that the number of asymptomatic carriers in the United Kingdom may be around 1 in 2000 people, which differs significantly from the number of clinically reported cases [4](#cjp290-bib-0004){ref-type="ref"}. This raises important concerns about the potential for further secondary transmission of vCJD and underscores the need for a sensitive, reliable, and fast diagnostic test.

With this aim, we have established an optimized assay to detect prions from suspected CJD cases in life, based on the *in vitro* amplification method Protein Misfolding Cyclic Amplification or PMCA.

Materials and methods {#cjp290-sec-0002}
=====================

Biological samples {#cjp290-sec-0003}
------------------

### Cerebrospinal fluid samples {#cjp290-sec-0004}

Cerebrospinal fluid (CSF) samples are sent to the laboratory on dry ice and stored at −80 °C prior to analysis. For this study CSF 14‐3‐3, tau protein and phosphorylated tau were analysed (For additional details, see supplementary material, Supplementary materials and methods). Consent for research was obtained for each sample and ethical approval was given by the MREC Scotland A (05/MRE00/67).

### vCJD and sCJD brain tissues {#cjp290-sec-0005}

Human brain tissue was obtained from the MRC Edinburgh Brain Bank. The specimens (frontal cortex) were sampled from a frozen half brain with the appropriate consent for research use (East of Scotland Research Ethics service REC 1, reference number 16/ES/0084).

Amplification procedure (PMCA/hsPMCA), proteolytic treatment, Western blotting, and criteria for positivity {#cjp290-sec-0006}
-----------------------------------------------------------------------------------------------------------

All procedures were performed in a category 3\* (\*with derogation) containment laboratory with strict adherence to health and safety protocols. The preparation of normal brain homogenate, human brain derived vCJD seed, preparation of amplification mixture, and amplification procedure are given in supplementary material, Supplementary materials and methods. Details of the proteolytic treatment, western blotting, and criteria for positivity [5](#cjp290-bib-0005){ref-type="ref"}, [6](#cjp290-bib-0006){ref-type="ref"} are also provided in supplementary material, Supplementary materials and methods.

Statistical analysis {#cjp290-sec-0007}
--------------------

Estimated sensitivity and specificity and 95% confidence intervals were calculated using MedCalc version 17.6.

Blinded samples {#cjp290-sec-0008}
---------------

CSF samples were provided as a blinded panel. They were decoded after the amplification analysis was performed and the experimental outcome evaluated.

Results and discussion {#cjp290-sec-0009}
======================

Based on the molecular susceptibility of PrP^C^ by the abnormal and misfolded isoform PrP^Sc^, the *in vitro* conversion systems such as Protein Misfolding Cyclic Amplification (PMCA) and Real‐Time Quaking Induced Conversion (RT‐QuIC) have provided important advances in the development of diagnostic opportunities for several protein misfolding disorders including human prion diseases [7](#cjp290-bib-0007){ref-type="ref"}, [8](#cjp290-bib-0008){ref-type="ref"}, [9](#cjp290-bib-0009){ref-type="ref"}, [10](#cjp290-bib-0010){ref-type="ref"}, [11](#cjp290-bib-0011){ref-type="ref"}, [12](#cjp290-bib-0012){ref-type="ref"}, [13](#cjp290-bib-0013){ref-type="ref"}, [14](#cjp290-bib-0014){ref-type="ref"}, [15](#cjp290-bib-0015){ref-type="ref"}.

Prior to optimization [5](#cjp290-bib-0005){ref-type="ref"}, [6](#cjp290-bib-0006){ref-type="ref"}, our standard PMCA protocol used transgenic mouse brain homogenate expressing the human *PRNP* gene homozygous for methionine at codon 129, as a substrate source of normal PrP^C^ for conversion (supplementary material, Figure S1A) [16](#cjp290-bib-0016){ref-type="ref"}. This substrate was seeded with vCJD prions. After proteolytic treatment (Proteinase K) and western blotting, the protease resistant core of PrP^Sc^ (PrP^res^) was immunodetected using the monoclonal antibody 3F4. Using a single 48 h round of standard PMCA, amplified PrP^Sc^ was detected after an initial dilution of vCJD brain seed in substrate of 1 × 10^−6^ -- 1 × 10^−7^ (supplementary material, Figure S1B). This level of sensitivity for a single round of PMCA is equivalent to that reported by others leading groups [8](#cjp290-bib-0008){ref-type="ref"}, [10](#cjp290-bib-0010){ref-type="ref"}, [17](#cjp290-bib-0017){ref-type="ref"}.

Detection of vCJD prions in human biological fluids such as whole blood, plasma, and urine demands high sensitivity of the PMCA, achieved partially by extensive rounds of *in vitro* amplification, causing delay in the reporting and involving laborious manipulation. By using serial rounds of amplification, vCJD prions have recently been detected in buffy coat, complete blood and plasma from vCJD patients after 2--4 rounds of PMCA [8](#cjp290-bib-0008){ref-type="ref"}, [10](#cjp290-bib-0010){ref-type="ref"}, [17](#cjp290-bib-0017){ref-type="ref"}. PrP^Sc^ was also identified in urine samples of vCJD patients after extensive amplification [13](#cjp290-bib-0013){ref-type="ref"}. However, the potential risk of cross‐contamination of samples due to the experimental handling is a concern when clinical samples need to be examined using prolonged experimental practices.

Here we report a [h]{.ul}ighly [s]{.ul}ensitive PMCA procedure (hsPMCA) to detect minute quantities of vCJD prions within a relatively short‐time period requiring minimal manipulation of the human clinical samples.

This method is able to readily detect vCJD prions diluted 100 billion‐fold (1 × 10^−11^) from the brain homogenate of a definite case of vCJD after a single round of amplification (supplementary material, Figure S2A). The sensitivity of hsPMCA showed a minimum of five‐fold increase when compared to standard PMCA (supplementary material, Figure S1B and S2B). The hsPMCA uses the combination of heparin (previously utilized with cellular substrates [15](#cjp290-bib-0015){ref-type="ref"}, [18](#cjp290-bib-0018){ref-type="ref"}) and transgenic substrate [5](#cjp290-bib-0005){ref-type="ref"}, [6](#cjp290-bib-0006){ref-type="ref"}, and the incorporation of beads [8](#cjp290-bib-0008){ref-type="ref"}, [10](#cjp290-bib-0010){ref-type="ref"}, [13](#cjp290-bib-0013){ref-type="ref"}, [17](#cjp290-bib-0017){ref-type="ref"}, [19](#cjp290-bib-0019){ref-type="ref"} as *in vitro* amplification enhancers. The effect of heparin and Teflon beads on the highly efficient conversion of CJD prions, but in particular of vCJD prions, may suggest direct interactions among the seed, substrate, and these two other hsPMCA components. The glycosaminoglycan heparin for example has been shown to bind to the normal and abnormal forms of the prion protein during the amplification of mouse‐adapted strains [18](#cjp290-bib-0018){ref-type="ref"}. Future studies are needed to clarify the nature of the *in vitro* interaction between human CJD prions and the amplification promoters, and its possible pathophysiological relevance. However, it would appear from our data that it is the incorporation of Teflon beads combined with the effect of heparin that may contribute to the high sensitivity reached by hsPMCA.

In view of the sensitivity of the hsPMCA assay for the detection of vCJD prions, we carried out a small pilot study, in which blinded CSF samples from two vCJD patients (one definite and one probable case), one sporadic CJD (sCJD) patient, and one other‐neurodegenerative disease (other‐ND) case were analysed by hsPMCA. After a single round of amplification, the two vCJD samples showed PrP^res^. No amplified product was detected for either the sCJD or the negative control samples (Figure [1](#cjp290-fig-0001){ref-type="fig"}A). To estimate the optimal volume of CSF required for amplification of vCJD prions, we further analysed a range of CSF volumes from these samples. Using the hsPMCA method, PrP^res^ was detected from a 2.5 µl volume of CSF from the definite case of vCJD. The probable case of vCJD required a higher volume (around 7 µl) of CSF (seed) to propagate prion *in vitro* after one round of amplification (Figure [1](#cjp290-fig-0001){ref-type="fig"}B). In reactions seeded with 10 and 16.8 µl CSF from the case of definite vCJD, no amplified PrP^res^ was detected, suggesting that higher concentrations of CSF components may have inhibited amplification (Figure [1](#cjp290-fig-0001){ref-type="fig"}B).

![Detection of vCJD prions in cerebrospinal fluid samples by hsPMCA. (A) CSF samples from one probable and one definite vCJD (vCJD1 and vCJD2, respectively), one sporadic CJD MM1 (sCJD1), one non‐CJD neurodegenerative disease case (Other‐ND), one non‐neurodegenerative case (non‐ND), and two reactions incubated with PBS were evaluated by hsPMCA. Reactions were seeded with a final volume of 8.4 µl of sample. Non‐amplified frozen ('F') and amplified ('S') samples were analysed. (B) A range of CSF sample volumes were considered for amplification using the same CSF panel. The samples were mixed with an equal volume of substrate (83.2 µl) and normalized to a final 100 µl reaction volume. The samples were subjected to a single round of amplification. Samples were treated with Proteinase K and evaluated by western blotting using 3F4 mAb. Reference molecular mass of electrophoretic markers is shown. (\*) Incomplete proteolytic digestion of PrP. \[N = 5; 2 vCJD (definite and probable), 1 sCJD, 1 non‐ND, 1 Other‐ND\].](CJP2-4-86-g001){#cjp290-fig-0001}

The failure of the sCJD MM1 CSF, and the low amplification of MM1 and MV2K brain samples to seed detectable PrP^res^ after hsPMCA, suggests that our methodology is not yet optimized for the detection of sCJD prions (supplementary material, Figures S2B and S2C). However, other *in vitro* amplification assays possess the levels of sensitivity and specificity to detect sCJD prions in CSF and in other clinical specimens [11](#cjp290-bib-0011){ref-type="ref"}, [12](#cjp290-bib-0012){ref-type="ref"}, [20](#cjp290-bib-0020){ref-type="ref"}.

Following on from the pilot study, we analysed a larger blinded panel of CSF samples comprising 10 definite vCJD cases, 6 sCJD MM1 cases, and 10 CSF samples from other neurodegenerative diseases, non‐neurodegenerative disease (non‐ND) and non‐CJD controls (Figure [2](#cjp290-fig-0002){ref-type="fig"}A, and Table [1](#cjp290-tbl-0001){ref-type="table-wrap"}). An additional group of 23 CSF samples from other‐ND/non‐ND/non‐CJD controls were also tested (Figure [3](#cjp290-fig-0003){ref-type="fig"}). In this analysis, 7.5 µl of CSF sample were included directly in the amplification mixture without any pre‐treatment of the CSF sample. After a single 48 h round of PMCA, six of the ten vCJD samples showed PrP^res^ by western blotting. The remaining four vCJD CSF samples showed robust amplification after a second round. In contrast, none of the sCJD MM1 or the negative controls showed any evidence of PrP^res^ formation after a single or second round of amplification (Figure [2](#cjp290-fig-0002){ref-type="fig"}A).

![Detection of vCJD prions in CSF samples in a larger blinded panel of *PRNP*‐codon 129MM and MV cases by hsPMCA. (A) A second blinded panel of CSF samples were evaluated including 10 definite vCJD codon 129MM (vCJD 3--12), 6 sCJD MM1 (sCJD 1--6), and 10 CSF controls from other neurodegenerative diseases (Other--ND), non‐CJD (non‐CJD), and non‐neurodegenerative diseases (non‐ND). A volume of 7.5 μl of CSF (for each sample) was mixed with 92.5 μl volumes of substrate and subjected to amplification. (B) Analysis of two vCJD *PRNP*‐codon 129MM cases, one possible (vCJD 14) and one probable (vCJD 15), a definite vCJD codon 129MV case reported recently in the United Kingdom (vCJD 13), and one non‐neurodegenerative (non‐ND) control were evaluated by hsPMCA. Two amplification rounds were completed (Round 1 and 2). Samples were treated with Proteinase K and evaluated by Western blotting using 3F4 mAb. The molecular mass of electrophoretic markers (MM) is shown. \[N = 30; 13 vCJD (definite, possible and probable), 6 sCJD, 5 non‐ND, 6 Other‐ND\].](CJP2-4-86-g002){#cjp290-fig-0002}

###### 

CJD and non‐CJD cases evaluated for vCJD prions by hsPMCA

  Diagnosis                                                                                                     Detection of vCJD prions by hsPMCA
  ------------------------------------------------------------------------------------------ ------------------ ------------------------------------
  vCJD                                                                                                          
  Definite                                                                                   11 (codon 129MM)   11/11
                                                                                             1 (codon 129MV)    1/1
  Possible                                                                                   1 (codon 129MM)    1/1
  Probable                                                                                   2 (codon 129MM)    2/2
                                                                                                                15/15
  sCJD                                                                                                          
  Definite                                                                                   5 (codon 129MM)    0/5
  Probable                                                                                   1 (codon 129MM)    0/1
                                                                                                                0/6
  Other neurodegenerative diseases[a](#cjp290-note-0002){ref-type="fn"}                      21                 0/21
  Non‐neurodegenerative diseases and improved cases[^†^](#cjp290-note-0003){ref-type="fn"}   14                 0/14

The 'other neurodegenerative diseases' group comprised cases of: Alzheimer\'s disease, Lewy body disease, Frontotemporal dementia, Cortical/strial/nigral degenerative disorder, Epinocerebellar ataxia, Paraneoplastic syndrome, Voltage gated K channelopathy, and Neuroaxonal dystrophy.

^†^The 'other non‐neurodegenerative diseases and improved cases' group comprise cases of: Diffuse large B cell lymphoma, Carcinomatosis of leptomeninges and brain, Progressive multifocal leukoencephalopathy, Angiotrophic lymphoma, Cerebrovascular disease, Small brain‐stem haemorrhages, Normal pressure hydrocephalus, and Intravascular B cell lymphoma.

![Analysis of vCJD prions in CSF samples versus non‐CJD controls by hsPMCA. Twenty three CSF samples including cases of other neurodegenerative diseases (Other--ND), non‐neurodegenerative diseases (Non‐ND), and non‐CJD controls (non‐CJD) were evaluated by hsPMCA for detection of vCJD prions. CSF from a definite vCJD case (vCJD2) and two unseeded reactions (PBS1‐PBS2) were included. Two rounds of amplification were performed (Round 1 and 2). The reactions were analysed for PrP^res^ after PK treatment and western blotting using 3F4 mAb. The molecular mass of electrophoretic markers (MM) is shown. \[N = 24; 1 vCJD, 8 non‐ND, 14 Other‐ND, 1 non‐CJD\].](CJP2-4-86-g003){#cjp290-fig-0003}

As a further test of the hsPMCA CSF assay, the second CSF blinded panel, also contained one possible and one probable vCJD codon 129MM case, and a third sample from the first definite codon 129MV vCJD case reported in the United Kingdom [21](#cjp290-bib-0021){ref-type="ref"}. The possible and probable codon 129MM cases were able to seed the hsPMCA producing detectable levels of PrP^res^ after one round of amplification. Moreover, the CSF sample derived from the vCJD codon 129MV case showed readily detectable levels of PrP^res^ after the second round of amplification (Figure [2](#cjp290-fig-0002){ref-type="fig"}B).

This study demonstrates for the first time that CSF samples from possible, probable, and definite cases of vCJD are able to propagate *in vitro*. The hsPMCA was able to support conversion of vCJD prions from codon 129MM and MV patients. Considering the number of samples analysed, we report an estimated sensitivity of 100% (95% CI, 69.15--100.00) and a specificity of 100% (95% CI, 89.42--100.00) of the hsPMCA assay within a 48--96 h period and with minimal manipulation of the clinical specimens. Currently, 178 cases of vCJD have been reported in the United Kingdom. It is also estimated that 1 in 2000 people are unidentified asymptomatic carriers. This study evaluates for the first time the presence of the vCJD prions in CSF samples of 15 symptomatic vCJD cases who are either MM or MV at *PRNP*‐codon 129, 6 sCJD, and 35 controls (supplementary material, Table S1). The relatively small absolute number of vCJD cases included in the study represents around 8.4% of the total number cases reported in the United Kingdom, not all of which have available CSF. Further analysis needs to be considered to confirm and extend the sensitivity and specificity values reported here, in a larger cohort of symptomatic, but also asymptomatic individuals. Direct comparison of our hsPMCA results with other previously published studies of CJD prions in human body fluid and tissues is challenging and complex. The use of different amplification protocols, types and substrate origin, amplification enhancers, sample treatment, and the use of human blood, urine, and CSF samples analysed complicate the comparisons and merit exhaustive review elsewhere. However, crucially, the hsPMCA assay provides a significant advantage in the development of a pre‐mortem diagnostic test for vCJD. Therefore, hsPMCA may be a valuable contribution in the surveillance for vCJD and, in combination with RT‐QuIC, may facilitate the differential diagnosis of sCJD and vCJD.
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**Figure S1.** Evaluation of human PrP expression levels in the humanized transgenic mouse model used for substrate and the ability to support *in vitro* conversion by PMCA

**Figure S2.** Amplification of CJD prions by hsPMCA
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**Table S1.** Details of the CJD cases evaluated by hsPMCA
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